Abstract
A combination chemotherapy of irinotecan (CPT-11) and cisplatin (CDDP) has been reported to be active for lung cancer. In the previous trial, however, diarrhoea and leucopenia became the major obstacle for sufficient dose escalation of CPT-11 to improve the treatment outcome. We conducted a phase I study to investigate whether the fractionated administration of CDDP and CPT-11 at escalated dose was feasible and could improve the treatment outcome. Twenty-four previously untreated patients with unresectable non-small-cell lung cancer (NSCLC) or extensive disease of small-cell lung cancer (SCLC) were eligible. Both CDDP and CPT-11 were given on days 1 and 8, and repeated every 4 weeks. The dose of CDDP was fixed at 60 mg m-2 and given by 1-h infusion before CPT-11 administration. The starting dose of CPT-11 was 40 mg m-2, and the dose was escalated by an increase of 10 mg m-2. The maximally tolerated dose of CPT-11 was determined as 60 mg m-2 because grade 4 haematological or grade 3 or 4 non-haematological toxicities developed in six patients out of 11 patients evaluated. Diarrhoea became a dose-limiting toxicity. The objective response rates were 76% for NSCLC and 100% for SCLC. The recommended dose of CPT-11 and CDDP in a phase II study will be 50 mg m-2 and 60 mg m-2 respectively.
Original language | English |
---|---|
Pages (from-to) | 984-990 |
Number of pages | 7 |
Journal | British Journal of Cancer |
Volume | 79 |
Issue number | 5-6 |
DOIs | |
Publication status | Published - 1999 |
Keywords
- Cisplatin
- Irinotecan
- Non-small-cell lung cancer
- Phase I study
- Small-cell lung cancer
ASJC Scopus subject areas
- Oncology
- Cancer Research